{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"49.5","upperLimit":"72.8","value":"61.6"},{"groupId":"OG001","lowerLimit":"45.4","upperLimit":"68.7","value":"57.3"},{"groupId":"OG002","lowerLimit":"54.6","upperLimit":"76.6","value":"66.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"77"}],"units":"Participants"}],"description":"pCR is defined as the absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. pCR is evaluated after 6 cycles of treatment and surgery or following withdrawal from the study whichever occurs sooner.","dispersionType":"95% Confidence Interval","groups":[{"description":"5-Fluorouracil, epirubicin with cyclophosphamide (FEC), trastuzumab and pertuzumab every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.","id":"OG000","title":"T+P Concomitant Anthracycline-based Chemotherapy"},{"description":"FEC every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 21 as adjuvant therapy post-surgery.","id":"OG001","title":"T+P Sequential Anthracycline-based Chemotherapy"},{"description":"Trastuzumab, carboplatin, docetaxel (TCH) and pertuzumab every three weeks, for six cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.","id":"OG002","title":"T+P Concomitant Non-Anthracycline Chemotherapy"}],"paramType":"NUMBER","populationDescription":"Intent to treat (ITT) population included all participants who were randomized to treatment.","reportingStatus":"POSTED","timeFrame":"At surgery, after 18 weeks (6 cycles) of treatment","title":"Efficacy: Percentage of Participants With Complete Pathological Response (pCR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}